Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 2
2018 2
2019 3
2020 4
2021 4
2022 6
2023 2
2024 6
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K, van der Wel TJWT, Zeverijn LJ, Geurts BS, Spiekman IAC, de Wit GF, Roepman P, Jansen AML, van der Noort V, Smit EF, Hoeben A, Hendriks LEL, van den Heuvel MM, Piet B, Herder GJM, Hashemi SMS, Gelderblom H, Verheul HMW, Voest EE, de Langen AJ. Verkerk K, et al. Among authors: jansen aml. Clin Cancer Res. 2024 Dec 2;30(23):5323-5332. doi: 10.1158/1078-0432.CCR-24-1925. Clin Cancer Res. 2024. PMID: 39352721 Clinical Trial.
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Zeverijn LJ, Geurts BS, Battaglia TW, van Berge Henegouwen JM, de Wit GF, Hoes LR, van der Wijngaart H, van der Noort V, Roepman P, de Leng WWJ, Jansen AML, Chalabi M, van Herpen CML, Devriese LA, Erdkamp FLG, Labots M, de Jonge MJA, Kerver ED, Bins AD, Leek LVM, Notohardjo JCL, van den Eertwegh AJM, Wessels LFA, Verheul HMW, Gelderblom H, van de Haar J, Voest EE. Zeverijn LJ, et al. Among authors: jansen aml. Clin Cancer Res. 2024 Oct 1;30(19):4339-4351. doi: 10.1158/1078-0432.CCR-24-0480. Clin Cancer Res. 2024. PMID: 39024037
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
Geurts BS, Zeverijn LJ, Leek LVM, van Berge Henegouwen JM, Hoes LR, van der Wijngaart H, van der Noort V, van de Haar J, van Ommen-Nijhof A, Kok M, Roepman P, Jansen AML, de Leng WWJ, de Jonge MJA, Hoeben A, van Herpen CML, Westgeest HM, Wessels LFA, Verheul HMW, Gelderblom H, Voest EE. Geurts BS, et al. Among authors: jansen aml. Clin Cancer Res. 2024 Sep 3;30(17):3735-3746. doi: 10.1158/1078-0432.CCR-24-0011. Clin Cancer Res. 2024. PMID: 38630551 Clinical Trial.
Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours.
Ebbelaar CF, Jansen AML, Speet LCM, Schutgens F, Zoetemeyer S, Cleton-Jansen AM, van Dijk MR, Breimer GE, Bloem LT, de Leng WWJ, van Doorn R, Suijkerbuijk KPM, Schrader AMR, Blokx WAM; MOLecular Evaluation of Melanocytic Ambiguous Tumours (MOLEMAT) Investigators. Ebbelaar CF, et al. Among authors: jansen aml. EBioMedicine. 2025 Apr;114:105643. doi: 10.1016/j.ebiom.2025.105643. Epub 2025 Mar 18. EBioMedicine. 2025. PMID: 40107205 Free PMC article.
Novel candidates in early-onset familial colorectal cancer.
Jansen AML, Ghosh P, Dakal TC, Slavin TP, Boland CR, Goel A. Jansen AML, et al. Fam Cancer. 2020 Jan;19(1):1-10. doi: 10.1007/s10689-019-00145-5. Epub 2019 Sep 25. Fam Cancer. 2020. PMID: 31555933 Free PMC article.
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.
Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, van der Velden DL, van de Haar J, Roepman P, de Leng WJ, Jansen AML, van Werkhoven E, van der Noort V, Huitema ADR, Gort EH, de Groot JWB, Kerver ED, de Groot DJ, Erdkamp F, Beerepoot LV, Hendriks MP, Smit EF, van der Graaf WTA, van Herpen CML, Labots M, Hoeben A, Morreau H, Lolkema MP, Cuppen E, Gelderblom H, Verheul HMW, Voest EE. Hoes LR, et al. Among authors: jansen aml. Clin Cancer Res. 2022 Apr 1;28(7):1402-1411. doi: 10.1158/1078-0432.CCR-21-3752. Clin Cancer Res. 2022. PMID: 35046062 Free PMC article.
BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.
van Not OJ, Blokx WAM, van den Eertwegh AJM, de Meza MM, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer M, van der Veldt AAM, Boers-Sonderen MJ, Jansen AML, Wouters MWJM, Suijkerbuijk KPM. van Not OJ, et al. Among authors: jansen aml. JCO Precis Oncol. 2022 Sep;6:e2200018. doi: 10.1200/PO.22.00018. JCO Precis Oncol. 2022. PMID: 36130145
34 results